{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:43:18Z","timestamp":1782949398523,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"University of Tokyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K15175"],"award-info":[{"award-number":["24K15175"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02261"],"award-info":[{"award-number":["25K02261"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50922-3","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:43:05Z","timestamp":1777563785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mathematical modeling of immune counter-regulation predicts efficacy of fractionated CD8+ T cell dosing strategies"],"prefix":"10.1038","volume":"16","author":[{"given":"Hiroki","family":"Kasai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Lysenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"50922_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2019.07.017","volume":"462","author":"X Jiang","year":"2019","unstructured":"Jiang, X. et al. Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities. Cancer Lett. 462, 23\u201332 (2019).","journal-title":"Cancer Lett."},{"key":"50922_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2293","volume":"11","author":"S Mardiana","year":"2019","unstructured":"Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci. Transl. Med. 11, eaaw2293 (2019).","journal-title":"Sci. Transl. Med."},{"key":"50922_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"50922_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: Mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"50922_CR5","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/ijc.28506","volume":"134","author":"A Hosoi","year":"2014","unstructured":"Hosoi, A. et al. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int. J. Cancer 134, 1810\u20131822 (2014).","journal-title":"Int. J. Cancer"},{"key":"50922_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1019195","volume":"4","author":"K Hirano","year":"2015","unstructured":"Hirano, K. et al. The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. Oncoimmunology 4, e1019195 (2015).","journal-title":"Oncoimmunology"},{"key":"50922_CR7","doi-asserted-by":"publisher","first-page":"eabi8075","DOI":"10.1126\/sciadv.abi8075","volume":"8","author":"DS Jones","year":"2022","unstructured":"Jones, D. S. et al. Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. Sci. Adv. 8, eabi8075 (2022).","journal-title":"Sci. Adv."},{"key":"50922_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01995-y","volume":"22","author":"NMF Abdalsalam","year":"2024","unstructured":"Abdalsalam, N. M. F. et al. MDSC: A new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun. Signal. 22, 612 (2024).","journal-title":"Cell Commun. Signal."},{"key":"50922_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106666","volume":"26","author":"RJ Beck","year":"2023","unstructured":"Beck, R. J., Sloot, S., Matsushita, H., Kakimi, K. & Beltman, J. B. Mathematical modeling identifies LAG3 and HAVCR2 as biomarkers of T cell exhaustion in melanoma. iScience 26, 106666 (2023).","journal-title":"iScience"},{"key":"50922_CR10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cels.2024.04.003","volume":"15","author":"MAR Strobl","year":"2024","unstructured":"Strobl, M. A. R. et al. To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy. Cell Syst. 15, 510-525.e6 (2024).","journal-title":"Cell Syst."},{"key":"50922_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1358478","volume":"15","author":"V Adhikarla","year":"2024","unstructured":"Adhikarla, V. et al. Designing combination therapies for cancer treatment: Application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy. Front. Immunol. 15, 1358478 (2024).","journal-title":"Front. Immunol."},{"key":"50922_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32554-z","volume":"13","author":"R Mehdizadeh","year":"2023","unstructured":"Mehdizadeh, R., Shariatpanahi, S. P., Goliaei, B. & R\u00fcegg, C. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: An in silico experiment. Sci. Rep. 13, 5875 (2023).","journal-title":"Sci. Rep."},{"key":"50922_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu, X. et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp. Hematol. Oncol. 13, 70 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"50922_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao, X. et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40, 367 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"50922_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-14-0098","volume":"3","author":"H Matsushita","year":"2015","unstructured":"Matsushita, H. et al. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN\u03b3-dependent cell-cycle arrest. Cancer Immunol. Res. 3, 26\u201336 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"50922_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113494","volume":"42","author":"JW Hickey","year":"2023","unstructured":"Hickey, J. W. et al. T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response. Cell Rep. 42, 113494 (2023).","journal-title":"Cell Rep."},{"key":"50922_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48711-2","volume":"9","author":"R Khazen","year":"2019","unstructured":"Khazen, R., M\u00fcller, S., Lafouresse, F., Valitutti, S. & Cussat-Blanc, S. Sequential adjustment of cytotoxic T lymphocyte densities improves efficacy in controlling tumor growth. Sci. Rep. 9, 12308 (2019).","journal-title":"Sci. Rep."},{"key":"50922_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","volume":"28","author":"IM Stromnes","year":"2015","unstructured":"Stromnes, I. M. et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28, 638\u2013652 (2015).","journal-title":"Cancer Cell"},{"key":"50922_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas, M. J. et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42, 1032-1050.e10 (2024).","journal-title":"Cancer Cell"},{"key":"50922_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-23-2040","volume":"84","author":"K Gallagher","year":"2024","unstructured":"Gallagher, K. et al. Mathematical model-driven deep learning enables personalized adaptive therapy. Cancer Res. 84, 1929\u20131941 (2024).","journal-title":"Cancer Res."},{"key":"50922_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).","journal-title":"Nat. Commun."},{"key":"50922_CR22","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656\u20132666 (2021).","journal-title":"J. Clin. Oncol."},{"key":"50922_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32866-0","volume":"13","author":"U Blache","year":"2022","unstructured":"Blache, U., Popp, G., D\u00fcnkel, A., Koehl, U. & Fricke, S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat. Commun. 13, 5225 (2022).","journal-title":"Nat. Commun."},{"key":"50922_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01229-3","author":"ZL Lamplugh","year":"2025","unstructured":"Lamplugh, Z. L., Wellhausen, N., June, C. H. & Fan, Y. Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-025-01229-3 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"50922_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677548","volume":"16","author":"MF Meza Pacheco","year":"2025","unstructured":"Meza Pacheco, M. F. & Tai, L.-H. Reprogramming the tumor microenvironment to boost adoptive T cell therapy. Front. Immunol. 16, 1677548 (2025).","journal-title":"Front. Immunol."},{"key":"50922_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long, A. H. et al. Reduction of MDSCs with All-trans Retinoic Acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4, 869\u2013880 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"50922_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi, Y. et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J. Immunother. Cancer 10, e004400 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"50922_CR28","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent Pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"50922_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009822","volume":"18","author":"N Ghaffari Laleh","year":"2022","unstructured":"Ghaffari Laleh, N. et al. Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput. Biol. 18, e1009822 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"50922_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2018.01.006","volume":"442","author":"SP Shariatpanahi","year":"2018","unstructured":"Shariatpanahi, S. P., Shariatpanahi, S. P., Madjidzadeh, K., Hassan, M. & Abedi-Valugerdi, M. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies. J. Theor. Biol. 442, 1\u201310 (2018).","journal-title":"J. Theor. Biol."},{"key":"50922_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4161\/cc.8.3.7608","volume":"8","author":"U Del Monte","year":"2009","unstructured":"Del Monte, U. Does the cell number 10(9) still really fit one gram of tumor tissue?. Cell Cycle 8, 505\u2013506 (2009).","journal-title":"Cell Cycle"},{"key":"50922_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaf559","volume":"41","author":"R Nakato","year":"2025","unstructured":"Nakato, R. & Nagai, L. A. E. ShortCake: An integrated platform for efficient and reproducible single-cell analysis. Bioinformatics 41, btaf559 (2025).","journal-title":"Bioinformatics"},{"key":"50922_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"50922_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ni1008-1091","volume":"9","author":"TSP Heng","year":"2008","unstructured":"Heng, T. S. P., Painter, M. W., Immunological Genome Project Consortium. The Immunological Genome Project: Networks of gene expression in immune cells. Nat. Immunol. 9, 1091\u20131094 (2008).","journal-title":"Nat. Immunol."},{"key":"50922_CR35","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"50922_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"50922_CR37","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","volume":"20","author":"AS Castanza","year":"2023","unstructured":"Castanza, A. S. et al. Extending support for mouse data in the Molecular Signatures Database (MSigDB). Nat. Methods 20, 1619\u20131620 (2023).","journal-title":"Nat. Methods"},{"key":"50922_CR38","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320 (2024).","journal-title":"Nat. Protoc."},{"key":"50922_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50922-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:44:28Z","timestamp":1782945868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50922-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50922"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50922-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20182"}}